Accessibility Statement Skip Navigation
  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing
  • Login
  • GDPR
  • Create a Free Account
Return to PRWeb homepage
  • News
  • Resources
  • Contact
When typing in this field, a list of search results will appear and be automatically updated as you type.

Searching for your content...

No results found. Please change your search terms and try again.
  • News in Focus
      • Browse News Releases

      • All News Releases
      • Multimedia Gallery

      • All Multimedia
      • All Photos
      • All Videos
  • Business & Money
      • Auto & Transportation

      • Aerospace, Defense
      • Air Freight
      • Airlines & Aviation
      • Automotive
      • Maritime & Shipbuilding
      • Railroads and Intermodal Transportation
      • Supply Chain/Logistics
      • Transportation, Trucking & Railroad
      • Travel
      • Trucking and Road Transportation
      • View All Auto & Transportation

      • Business Technology

      • Blockchain
      • Broadcast Tech
      • Computer & Electronics
      • Computer Hardware
      • Computer Software
      • Data Analytics
      • Electronic Commerce
      • Electronic Components
      • Electronic Design Automation
      • Financial Technology
      • High Tech Security
      • Internet Technology
      • Nanotechnology
      • Networks
      • Peripherals
      • Semiconductors
      • View All Business Technology

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Financial Services & Investing

      • Accounting News & Issues
      • Acquisitions, Mergers and Takeovers
      • Banking & Financial Services
      • Bankruptcy
      • Bond & Stock Ratings
      • Conference Call Announcements
      • Contracts
      • Cryptocurrency
      • Dividends
      • Earnings
      • Earnings Forecasts & Projections
      • Financing Agreements
      • Insurance
      • Investments Opinions
      • Joint Ventures
      • Mutual Funds
      • Private Placement
      • Real Estate
      • Restructuring & Recapitalization
      • Sales Reports
      • Shareholder Activism
      • Shareholder Meetings
      • Stock Offering
      • Stock Split
      • Venture Capital
      • View All Financial Services & Investing

      • General Business

      • Awards
      • Commercial Real Estate
      • Corporate Expansion
      • Earnings
      • Environmental, Social and Governance (ESG)
      • Human Resource & Workforce Management
      • Licensing
      • New Products & Services
      • Obituaries
      • Outsourcing Businesses
      • Overseas Real Estate (non-US)
      • Personnel Announcements
      • Real Estate Transactions
      • Residential Real Estate
      • Small Business Services
      • Socially Responsible Investing
      • Surveys, Polls and Research
      • Trade Show News
      • View All General Business

  • Science & Tech
      • Consumer Technology

      • Artificial Intelligence
      • Blockchain
      • Cloud Computing/Internet of Things
      • Computer Electronics
      • Computer Hardware
      • Computer Software
      • Consumer Electronics
      • Cryptocurrency
      • Data Analytics
      • Electronic Commerce
      • Electronic Gaming
      • Financial Technology
      • Mobile Entertainment
      • Multimedia & Internet
      • Peripherals
      • Social Media
      • STEM (Science, Tech, Engineering, Math)
      • Supply Chain/Logistics
      • Wireless Communications
      • View All Consumer Technology

      • Energy & Natural Resources

      • Alternative Energies
      • Chemical
      • Electrical Utilities
      • Gas
      • General Manufacturing
      • Mining
      • Mining & Metals
      • Oil & Energy
      • Oil and Gas Discoveries
      • Utilities
      • Water Utilities
      • View All Energy & Natural Resources

      • Environ­ment

      • Conservation & Recycling
      • Environmental Issues
      • Environmental Policy
      • Environmental Products & Services
      • Green Technology
      • Natural Disasters
      • View All Environ­ment

      • Heavy Industry & Manufacturing

      • Aerospace & Defense
      • Agriculture
      • Chemical
      • Construction & Building
      • General Manufacturing
      • HVAC (Heating, Ventilation and Air-Conditioning)
      • Machinery
      • Machine Tools, Metalworking and Metallurgy
      • Mining
      • Mining & Metals
      • Paper, Forest Products & Containers
      • Precious Metals
      • Textiles
      • Tobacco
      • View All Heavy Industry & Manufacturing

      • Telecomm­unications

      • Carriers and Services
      • Mobile Entertainment
      • Networks
      • Peripherals
      • Telecommunications Equipment
      • Telecommunications Industry
      • VoIP (Voice over Internet Protocol)
      • Wireless Communications
      • View All Telecomm­unications

  • Lifestyle & Health
      • Consumer Products & Retail

      • Animals & Pets
      • Beers, Wines and Spirits
      • Beverages
      • Bridal Services
      • Cannabis
      • Cosmetics and Personal Care
      • Fashion
      • Food & Beverages
      • Furniture and Furnishings
      • Home Improvement
      • Household, Consumer & Cosmetics
      • Household Products
      • Jewelry
      • Non-Alcoholic Beverages
      • Office Products
      • Organic Food
      • Product Recalls
      • Restaurants
      • Retail
      • Supermarkets
      • Toys
      • View All Consumer Products & Retail

      • Entertain­ment & Media

      • Advertising
      • Art
      • Books
      • Entertainment
      • Film and Motion Picture
      • Magazines
      • Music
      • Publishing & Information Services
      • Radio & Podcast
      • Television
      • View All Entertain­ment & Media

      • Health

      • Biometrics
      • Biotechnology
      • Clinical Trials & Medical Discoveries
      • Dentistry
      • FDA Approval
      • Fitness/Wellness
      • Health Care & Hospitals
      • Health Insurance
      • Infection Control
      • International Medical Approval
      • Medical Equipment
      • Medical Pharmaceuticals
      • Mental Health
      • Pharmaceuticals
      • Supplementary Medicine
      • View All Health

      • Sports

      • General Sports
      • Outdoors, Camping & Hiking
      • Sporting Events
      • Sports Equipment & Accessories
      • View All Sports

      • Travel

      • Amusement Parks and Tourist Attractions
      • Gambling & Casinos
      • Hotels and Resorts
      • Leisure & Tourism
      • Outdoors, Camping & Hiking
      • Passenger Aviation
      • Travel Industry
      • View All Travel

  • Policy & Public Interest
      • Policy & Public Interest

      • Advocacy Group Opinion
      • Animal Welfare
      • Congressional & Presidential Campaigns
      • Corporate Social Responsibility
      • Domestic Policy
      • Economic News, Trends, Analysis
      • Education
      • Environmental
      • European Government
      • FDA Approval
      • Federal and State Legislation
      • Federal Executive Branch & Agency
      • Foreign Policy & International Affairs
      • Homeland Security
      • Labor & Union
      • Legal Issues
      • Natural Disasters
      • Not For Profit
      • Patent Law
      • Public Safety
      • Trade Policy
      • U.S. State Policy
      • View All Policy & Public Interest

  • People & Culture
      • People & Culture

      • Aboriginal, First Nations & Native American
      • African American
      • Asian American
      • Children
      • Diversity, Equity & Inclusion
      • Hispanic
      • Lesbian, Gay & Bisexual
      • Men's Interest
      • People with Disabilities
      • Religion
      • Senior Citizens
      • Veterans
      • Women
      • View All People & Culture

  • Hamburger menu
  • Cision PRWeb provides efficient communication tools to continuously engage with target audiences across multiple online channels
  • Create a Free Account
    • ALL CONTACT INFO
    • Contact Us


      11AM ET Sunday – 8PM ET Friday

  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • News in Focus
    • Browse All News
    • Multimedia Gallery
  • Business & Money
    • Auto & Transportation
    • Business Technology
    • Entertain­ment & Media
    • Financial Services & Investing
    • General Business
  • Science & Tech
    • Consumer Technology
    • Energy & Natural Resources
    • Environ­ment
    • Heavy Industry & Manufacturing
    • Telecomm­unications
  • Lifestyle & Health
    • Consumer Products & Retail
    • Entertain­ment & Media
    • Health
    • Sports
    • Travel
  • Policy & Public Interest
  • People & Culture
    • People & Culture
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR
  • Send a Release
  • Sign up
  • Log in
  • Resources
  • RSS
  • GDPR

Helixmith announces the development of botanical therapeutic product for respiratory diseases, TADIOS

Helixmith announces encouraging animal model efficacy data has been published in the Journal of Ethnopharmacology for their botanical therapeutic product for respiratory diseases. A clinical trial of 100 patients diagnosed with COVID-19 to begin soon in India.


News provided by

Helixmith Co., Ltd

Jan 14, 2021, 09:00 ET

Share this article

Share toX

Share this article

Share toX


SAN DIEGO, Jan. 14, 2021 /PRNewswire-PRWeb/ -- Helixmith Co., Ltd. has announced that TADIOS (HX110), a respiratory treatment developed by the company, showed lung damage-suppressing capability in an acute lung injury mouse model. The results have been published in the Journal of Ethnopharmacology. Helixmith plans to conduct a clinical trial in India to assess if TADIOS can be used as a COVID-19 treatment. Helixmith has signed an agreement with a contract research organization (CRO) that has extensive experience and capacities in the conduct of clinical trials in India. The clinical trial will be conducted in accordance with the regulations of the Ministry of AYUSH, India's traditional medicine regulatory body, and will begin in February with 100 subjects.

Publication Link: https://www.sciencedirect.com/science/article/abs/pii/S0378874121000210

“The individual herbs in TADIOS have historical records of safety and efficacy in Asian countries. Through this clinical trial, we hope to confirm clinical effectiveness of this combination of botanical herbs in improving symptoms of COVID-19 patients,” said Seungshin Yu, CEO of Helixmith.

Post this

Summary of Publication:

TADIOS is a botanical formulation composed of three herbs. Each of the plant species incorporated in TADIOS has been used individually in Asia as a food ingredient and/or medicinal herb for the treatment of various respiratory diseases. Helixmith's research team found in animal models that, when the three herbs are combined at an appropriate ratio and processed in a specific way, the therapeutic effect can be significantly increased.

Acute respiratory distress syndrome (ARDS) is a respiratory failure produced by uncontrolled excessive inflammation and oxidative stress in the lungs. The causes are diverse, including bacteria, viruses, and environmental chemicals. An acute lung injury mouse model with a high degree of pulmonary inflammation induced by a lipid polysaccharide (LPS) is one of the most frequently used animal models in ARDS studies. In the LPS-induced acute lung injury (ALI) model, lung damage progresses very rapidly and extensively. Effective treatment in this model may indicate the possibility of preventing or treating clinical symptoms in respiratory diseases such as that caused by SARS-CoV-2.

In the described study, the researchers used the LPS-induced ALI model and found that lung damage was significantly inhibited in mice treated with TADIOS. The effects appear to result from the control of excessive production of inflammatory and oxidative molecules such as TNF-alpha, IL-6, IL-1beta and ROS. The potential molecular mechanism underlying TADIOS' anti-inflammatory and anti-oxidative activities is control of the Nrf2-HO-1 pathway. Thus, rather than acting on SARS-CoV-2 itself, TADIOS may instead prevent or inhibit disease progression upon viral infection through a reduction of inflammatory and oxidative response.

Based on the findings, Helixmith has decided to conduct a double-blind placebo-controlled clinical study on patients diagnosed with COVID-19 to investigate whether TADIOS can prevent or alleviate disease progression.

Clinical Trial:

The upcoming TADIOS clinical trial will be conducted in India, where there is a high rate of COVID-19 infection and unmet medical need. The study will target patients diagnosed with COVID-19 who have mild to moderate clinical symptoms.

The plan is to enroll 100 patients who have been diagnosed with COVID-19 via RT-PCR test. Patients will be randomized 1:1, 50 subjects to the TADIOS group and 50 to the placebo group. TADIOS will be added as an adjuvant to the COVID-19 standard treatment regimen under double-blinded conditions, and its efficacy and safety will be assessed at 10 days and 14 days after administration. Various biochemical indicators, such as TNF-alpha, CRP, IL-6, IL-1ra, Hb, and ferritin, will be measured at 10 days post administration or at the time of discharge if earlier than 10 days. Anti-inflammatory and anti-oxidative activity will also be assessed. Clinical symptom improvement will be determined using an 8-point sequence scale designed by WHO. Quality of life, fatigue, and hospitalization period will be evaluated. The study is expected to take six to eight months once EC approval is obtained at all clinical sites.

COVID-19 Unmet Need:

Respiratory damage caused by COVID-19 is known to include extensive inflammatory reactions and oxidative stress. For this reason, treatments aimed at suppressing inflammation through immune control are being developed, but indiscriminate immunosuppressants such as steroids can have safety problems. Therefore, the development of safe and effective treatments is urgently needed.

More than 80% of people infected with COVID-19 are known to be asymptomatic or have mild symptoms, but fatality rates are high for people with underlying conditions such as diabetes and chronic obstructive pulmonary disease. In addition, 3-5% of infected patients are known to develop acute respiratory failure or ARDS; therefore, treatments that can mitigate disease progression or inhibit respiratory damage are needed.

About Helixmith Co., Ltd.

Helixmith is a gene therapy company based in Seoul and San Diego, developing new and innovative biopharmaceuticals to tackle previously untreated diseases. The company has an extensive gene therapy pipeline, including a CAR-T program targeting several different types of solid tumors and an AAV vector program targeting neuromuscular diseases. Engensis (VM202), the most advanced pipeline candidate, is a plasmid DNA therapy being studied for diabetic peripheral neuropathy, diabetic foot ulcers, claudication, amyotrophic lateral sclerosis (Phase 2 beginning in early 2021), coronary artery disease, and Charcot-Marie-Tooth disease. The company is listed on KOSDAQ.

Helixmith clinical development and manufacturing activities are based in San Diego, California, where the company co-owns a cGMP-ready DNA production facility, Genopis, Inc., an affiliated CDMO also in San Diego. Genopis serves both Helixmith and external customers in need of plasmid DNA for medical purposes.

Media Contact

Jennifer Guzman, Helixmith Co., Ltd, 760-291-7245, [email protected]

SOURCE Helixmith Co., Ltd

Modal title

Contact PRWeb

  • 11AM ET Sunday – 8PM ET Friday
  • Contact Us

About PRWeb

  • About PRWeb
  • Partners
  • Partnership Programs
  • Editorial Guidelines
  • Resources

Why PRWeb

  • Why PRWeb
  • How It Works
  • Who Uses It
  • Pricing

Accounts

  • Create a Free Account
  • Log in
  • Contact Us

Do not sell or share my personal information:

  • Submit via [email protected] 
  • Call Privacy toll-free: 877-297-8921

Contact Cision

Products

About

My Services
  • All News Releases
  • Online Member Center
  • ProfNet
Cision Distribution Helpline
888-776-0942
  • Legal
  • Site Map
  • RSS
  • Cookie Settings
Copyright © 2025 Cision US Inc.